CLOSER LOOK

MEMORANDUM

MiniMed launches MiniMed Go smart MDI system in the US, combining InPen with Abbott's Instinct CGM – May 27, 2026

Connected MDI platform integrates insulin dosing, CGM data, and personalized guidance within a single mobile app

MiniMed announced today the US launch of MiniMed Go, a connected smart multiple daily injection (MDI) platform. MiniMed Go integrates the InPen smart insulin pen with the Instinct CGM sensor (made by Abbott exclusively for MiniMed) and a unified mobile application. The system is designed for people managing insulin dosing through MDI and combines real-time glucose data, insulin-dose tracking, dose reminders, dose-calculator functionality, and personalized guidance in a single interface. The launch follows FDA clearance in January 2026 and comes after an initial rollout in Europe using MiniMed's Simplera sensor platform. In the US, Simplera sensor compatibility with MiniMed Go remains under FDA review.

Table of Contents

1. MiniMed Go combines connected insulin dosing with CGM guidance
2. Connected MDI launch in the US reflects MiniMed's broader portfolio strategy
3. Close Concerns' Questions

MiniMed Go combines connected insulin dosing with CGM guidance

MiniMed Go integrates several previously separate diabetes-management components into a single connected platform. The system combines:

- The InPen smart insulin pen;
- Abbott's Instinct CGM sensor and MiniMed's Simplera CGM sensor;
- Insulin dose reminders and missed-dose alerts;
- Dose-calculator functionality; and
- Glucose- and insulin-trend visualization within a unified mobile app.



Source: MiniMed

According to MiniMed, the system is intended to simplify daily insulin management while helping users better understand how insulin dosing, meals, and glucose patterns interact over time. InPen additionally provides action-oriented guidance when users miss or miscalculate insulin doses. The CareLink data management platform integration allows healthcare providers to review dosing and glucose data remotely.

While insulin pumps and AID systems continue expanding globally, most insulin users still do so through injections. Compared to traditional MDI workflows, connected MDI platforms such as MiniMed Go may help address user challenges around insulin timing and dose tracking. These platforms may offer a lower-cost and lower-burden pathway toward more data-driven insulin management without requiring a transition to pump therapy.

Connected MDI launch in the US reflects MiniMed's broader portfolio strategy

While the company remains strongly associated with insulin pumps and AID systems such as MiniMed 780G and the newly announced MiniMed Flex, management has previously reiterated its focus on serving multiple diabetes management populations across both pump and MDI modalities.

The differing US and European launches may also provide insight into how MiniMed could pursue more flexible CGM integration strategies across geographies depending on regulatory timing, reimbursement dynamics, and existing commercial relationships. For example, in Europe, the system launched using MiniMed's Simplera sensor rather than Abbott's Instinct platform.

Close Concerns' Questions

1. How will MiniMed Go be promoted relative to standalone InPen offerings?
2. What populations does MiniMed view as the primary target users for connected MDI systems?
3. How do reimbursement pathways for connected MDI systems compare to traditional MDI therapy?
4. Will MiniMed pursue a European launch of MiniMed Go integrated with the Instinct CGM?

-- by Riya Chatterjee, Nour Khachemoune, Monica Oxenreiter, and Kelly Close